Aura Biosciences, Inc. Capital Expenditures Incurred but Not yet Paid
Aura Biosciences, Inc. (AURA) reported Capital Expenditures Incurred but Not yet Paid of $7.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$13.00K.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $20.00K.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $91.00K.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $0.00.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $91.00K, a 160.00% increase from fiscal 2024.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $35.00K, a 62.77% decline from fiscal 2023.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $94.00K, a 47.78% decline from fiscal 2022.
- Aura Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $180.00K, a 53.37% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $7.00K 10-Q · filed 2026-08-11 | $98.00K derived: sum of 3 quarters · filed 2026-08-11 | $98.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-11 | $111.00K derived: sum of 2 quarters · filed 2026-05-11 | $111.00K derived: sum of 3 quarters · filed 2026-05-11 | $111.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $91.00K derived: sum of 2 quarters · filed 2026-03-30 | $91.00K derived: sum of 3 quarters · filed 2026-08-11 | $91.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-13 | -$117.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | -$117.00K derived: sum of 3 quarters · filed 2026-08-11 | -$155.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | -$117.00K derived: sum of 2 quarters · filed 2026-05-11 | -$155.00K derived: sum of 3 quarters · filed 2026-05-11 | -$87.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$155.00K derived: sum of 2 quarters · filed 2026-03-30 | -$87.00K derived: sum of 3 quarters · filed 2026-03-30 | $35.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $30.00K derived: sum of 2 quarters · filed 2025-11-13 | $152.00K 10-Q · filed 2025-11-13 | $181.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $68.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $190.00K 10-Q · filed 2025-08-13 | $219.00K derived: sum of 3 quarters · filed 2025-08-13 | $271.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $122.00K 10-Q · filed 2025-05-15 | $151.00K derived: sum of 2 quarters · filed 2025-05-15 | $203.00K derived: sum of 3 quarters · filed 2025-05-15 | $201.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $81.00K derived: sum of 2 quarters · filed 2025-03-24 | $79.00K derived: sum of 3 quarters · filed 2025-03-24 | $94.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $50.00K derived: sum of 2 quarters · filed 2024-11-12 | $65.00K 10-Q · filed 2024-11-12 | $221.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.00K 10-Q · filed 2024-08-08 | $169.00K derived: sum of 3 quarters · filed 2024-08-08 | -$233.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $15.00K 10-Q · filed 2024-05-09 | $171.00K derived: sum of 2 quarters · filed 2024-05-09 | -$231.00K derived: sum of 3 quarters · filed 2024-05-09 | -$116.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$246.00K derived: sum of 2 quarters · filed 2024-03-27 | -$131.00K derived: sum of 3 quarters · filed 2024-03-27 | $180.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | -$402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$287.00K derived: sum of 2 quarters · filed 2023-11-09 | $24.00K 10-Q · filed 2023-11-09 | $251.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $426.00K 10-Q · filed 2023-08-09 | $653.00K derived: sum of 3 quarters · filed 2023-08-09 | $660.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $311.00K 10-Q · filed 2023-05-11 | $538.00K derived: sum of 2 quarters · filed 2023-05-11 | $545.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $234.00K derived: sum of 2 quarters · filed 2023-03-15 | $386.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $159.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $152.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |